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Chapter 8

CONTRACEPTION
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United States of America, Donetsk Medical University, Donetsk,
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Contraception is an important concept for sexually active
adolescent females to understand who do not wish to become
pregnant. This chapter reviews important, effective, and safe
contraceptive methods that can be used by female youth. These
methods include abstinence, oral contraception, contraceptive patch.
*
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mini-pills, emergency contraceptives, injectable contraception
(DMPA). implants (lmplanon), intravaginal ring, vaginal barrier
contraceptives, intrauterine devices, and natural family planning.
Promotion of se1rnal responsibility should be the charge of health
professionals caring for adolescents and young adults.

INTRODUCTION
An important issue for human beings is the acquisition of normal sexual
healtl1, including the understanding and application of reproductive
health when needed (1-5). Unfortunately, comprehensive sexuality
education is not a topic provided to many of our children, adolescents or
college students in the United States (5). The median age at first
intercourse of 16 years in the United States is comparable to the age of
coital initiation in other developed countries such as Canada, countries of
Western Europe (France, Great Britain), countries of Eastern Europe and
Eurasia (Russia) (6-11).
Students who were sexually active in high school may continue to be
at risk for pregnancy and sexually transmitted diseases in their college
life; those youth who chose abstinence at one point may abandon this
concept as they mature, choosing coital behavior with one or more
partners in junior high school, high school, or college (8,12-14). There
are over 15 million cases of sexually transmitted diseases in the United
States, and over 60% of these occur in young people under 25 years of
age) (4,7).
All youth who are sexually active, including those with chronic
illness, should be provided with appropriate contraceptive counselling
and contraceptive prescription if they are not willing to accept abstinence
(1,2,15-17). Since millions of female adolescents are sexually active, it is
important that clinicians caring for them provide appropriate sexuality
counselling, covering such topics as safe sex. contraception, and
STD/AIDS prevention (12,18-21). Reasons for not using contraception
include being abstinent, wishing to become pregnant, concluding they or
their partners were sterile, fear of contraceptive "side effects" (such as
cancer
gain),
breast
or
religious
objections
regarding
contraception, lack of clinician education about contraceptives, history of

Contraception

415

contraception or abortion, failure of insurance to cover contraception,
and others (1,2,22-27). Approximately half of adolescent pregnancies
occur within the first six months after the initiation of coital behaviour,
while adolescents wait one year or more after starting coitus to seek
advice from clinicians about effective contraception. Higher
socioeconomic status and education are factors that lead to an increase in
delay in coitus and willingness to use effective contraption if sexually
active (28). Although adolescent pregnancy rates have dropped 33% in
the United Sates from the early 1990s to 2003, the rates in the U.S. are
the highest in developed countries with a birth rate in 15 to 19 year olds
at 41.7/1 ,000 (14,29).
A number of safe and effective contraceptive methods are available
(1-4,15,18,20,30,31) (see table 1). The gap between efficacy of perfect
use of contraceptives (e.g., correct, consistent, and continued use of a
chosen contraceptive method) and typical use leads to millions of
unintended pregnancies each year (1,2,4,32-36). Efficacy rates of
contraceptives are noted in table 2 (35,36). The barrier methods (i.e.,
condoms, diaphragms, cervical caps, vaginal sponges, female condoms,
and vaginal spermicides) can be used quite effectively by motivated high
school or college students who are taught how to use them; periodic
abstinence has higher pregnancy rates, but is potentially an effective
contraceptive method. The female's comfort for insertion of barrier
methods is crucial for maximum contraceptive efficacy for these
methods, and thus, they are not appropriate for many adolescent who do
not have this comfort level.
Norplant, an effective method in which six progesterone capsules are
inserted subcutaneously into the upper arm, was removed from the
United States market in 2000. Implanon, a single progesterone rod
implant, has now replaced Norplant in the Uniled States. The intrauterine
device is an excellent contraceptive, but has been tainted with the image
of inducing pelvic inflammatory disease ( 1,37). These contraceptive
methods are discussed later in this discussion.
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Table 1. Contraceptive methods

Abstinence
Combined Oral Contraceptives (COCs)
Contraceptive patch
Mini-pills (Progestin-only pills; POPs)

Emergency contraceptives
Injectable Contraceptives

Depo-Provera® (Depo-medroxy-progesterone acetate
Lunelle® (estradiol cypionate and medroxyprogesterone
acetate)
Implants
Norplant I (withdrawn from the US market in 2000)
Implanon (one rod system with etonogestrel)
Jadelle (Norplant II: two silastic rods with levonorgestrel)
Intravaginal ring (NuvaRing)
Intrauterine Devices

Progestasert® IUD (with progesterone)
ParaGard® (Copper T380A IUD)
Mirena® (IUD with levonorgestrel)
Vaginal barrier contraceptives
Cervical cap (Prentif Cavity-rim®)
Condoms (male)
Contracepti ve sponge (vaginal)
Diaphragm
Female condom (Reality®)
Spermicides (vaginal)
Sterilization (female sterilization, vasectomy)
Physiological methods/natural family planning
Coitus interruptus
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Table 2. Efficacy of contraceptives (40,41)
Contraceptive Efficacy

First Year Failure Rate
Typical Use

Perfect Use

Combined OCs

3-8

0.1

Progesterone IUD

2

1.5

Copper T IUD

0.8

0.6

Mirena IUD

0.2

0.1

DMPA

0.3
0.05

0.3
0.05

Norplant

The choice of currently available contraceptive methods has
increased considerably in recent years, offering females of reproductive
age a variety of different methods that retlect their various needs and
lifestyles. A number of contraceptive methods have received United
States Food and Drug Administration (FDA) approval over the past two
decades (see table 3), including emergency contraceptives (Preven, Plan
B), Depo-Provera (DMPA), the cervical cap, Lunelle (injectable
contraceptive with estrogen), Mirena (an IUD with levonorgestrel), a
contraceptive patch (Evra), an intravaginal ring (NuvaRing), and
implants such as Implanon (28,38-40).
Table 3. FDA approval history for contraceptives

1.
2.
3.
4.
5.
6.
7.
8.
9.

12/90: Norplant (Withdrawn from US Market in 2000)
10/92: Depo-Provera
9/98: Preven Kit
7/99: Plan B
10/00: Lunelle, "injectable pill" (withdrawn from the US Market)
12/00: Mirena IUD
10/01: Nuva Ring (vaginal ring)
11/0l: Evra Patch
2006 Implanon (single rod)
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Technology has expanded over the past decade to include various
ways of contraceptive steroid release (see table 4), leading to a number of
potential advantages (see table 5). After OCPs were developed over 45
years ago, the emphasis has been on having newer pill formulations with
lower doses of estrogens as well as various progestins and developing
phasic dosing regimens. Recently, newer delivery systems of hormones
have been developed to help decrease contraceptive failure rates
associated with incorrect use of contraceptives. For example, the patch
and ring are user controlled and easy to discontinue. thus, being more
appealing to some females (seetable4) (15,41).
Table 4. Methods to deliver steroids
Pills
Patch
Injectables
Hormone-releasing IUDs
Implants
Vaginal rings
Table 5. Advantages of new contraceptive methods
Increases range of new contraceptive methods
Very effective and easy to use
Reversible, but not daily hormonal effects with better compliance
Low hormone doses
Continuous low hormone levels

ORAL CONTRACEPTIVES
One of the most popular contraceptive methods is the oral contraceptive
pill (OCP) and there are over 145 brands of OCPs available worldwide;
most OCPs contain both a synthetic estrogen and synthetic progestogen
(see table 6) (l ,2,42). The estrogen is usually ethinyl estradiol (EE), but a
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few brands contain mestranol. In general, it is thought that 30-35 mcg EE
is equivalent to 50 mcg of mestranol (see table 6). There are many
progestogens available, including norethindrone, levonorgestrel,
gestodene, desogestrel, norgestimate, ciproterone acetate, and
drospirenone. Drospirenone is a newer synthetic progestin chemically
related to spironolactone (43). Estrogen may lead to nausea, headache,
weight gain, breast tenderness, and breast enlargement; progestins may
lead to unfavorable changes in low density lipoprotein (LDL) and high
density lipoprotein (HDL) cholesterol, fatigue, depression, and menstrual
changes. Questions to pose to the adolescent interested in oral
contraceptives are listed in table 7.
Table 6. Combined oral contraceptive hormones
Estrogen
Ethinyl Estradiol
Mestranol (3 brands)
Progestins
Norgestrel
Levonorgestrel
Norethindrone
Norgestimate
Norethindrone acetate
Desogestrel
Ethynodiol acetate
Drospirenone
Gesrodene: (not available in the US)
Table 7. Questions to pose to teens requesting contraception
1. What methods have you used before?
2. What are your worries about this method?
3. What method do your friends use? What did they say about these
methods?
4. Do you think you can use this method correctly?
5. Do you worry about your weight? Are you dieting?
6. Can you deal with unexpected bleeding?
7. Have you beard of some negative comments about OCP use
(e.g., weight gain and infertility?)
8. Do you know the minor OCP side effects?
9. Do you have any questions I have not answered?
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OCPs prevent pregnancy by inhibiting ovulation, increasing cervical
mucus viscosity, causing endometrial atrophy, and changing tubal
transport mechanisms (1). Non-contraceptive benefits of the oral
contraceptive are listed in table 8 (l,2,4,15,44). Most brands are
manufactured as 21 or 28 day packs. The 21 day packs have seven days
of placebo pills, so that the adolescent continues to take a pill each day of
the cycle. Newer variations include brands which have only two placebo
days in each 28 day cycle. Also available is an OCP dial pack dispenser,
with each pill numbered and a dial that only turns in one direction. There is
no combined oral contraceptive pill brand shown to be more effective
than any other brand in preventing pregnancy; thus, any brand the female
wishes to take to prevent unwanted pregnancy is acceptable (1,2,45).
Some OCPs can be counterfeit and this possibility must be considered if
pills are not obtained in pharmacies or other trusted places (46). Along
with OCPs, condoms are also recommended to reduce the risk for
sexually transmitted diseases (47,48).
Table 8. Non-contraceptive benefits of combined oral
contraceptives (1,2,4)

1. Treatment for dysmenorrhea
2. Treatment for dysfunctional uterine bleeding
3. Treatment for premenstrual syndrome
4. Decreased risk for ovarian and endometrial cancer
5. Decreased risk for symptomatic pelvic inflammatory disease
6. Treatment for polycystic ovary syndrome (PCOS)
7. Treatment of acne vulgaris
8. Treaunent for premature ovarian failure
9. Treatment for endometriosis
1O. Treatment of hypothalamic amenorrhea due to eating disorders, exercise,
stress
11. Decreased Mittelschmei1z
12. Prevention of ovarian cyst disease
13. Lower incidence of ectopic pregnancy (reduced risk by 90%)
14. Protective for rheumatoid arthritis
15. Possible benefit in prevention/treatment of disorders associated with
decreased bone mineral density
16. Possible benefit in the prevention of the development of leiomyomata
uteri

Contraception

421

Newer OCP brands now available include Alesse and Levlite (both
with 20 mcg EE and 0.1 mg levonorgestrel), Apri (with 30 mcg EE and
0.15 mg desogestrel), Desogen (30 mcg EE with 0.15 mg desogestrel),
Estrostep (EE increasing from 20-35 mcgs over three weeks with 1 mg
norethindone), Kariva (multiphasic with three levels of EE [20,0, 10] and
0.15 mg desogestrel), and Mircette (multiphasic: three weeks of 20 mcgs
of EE and 0.15 mg desogestrol, then 2 placebo pills. then 5 days of 1O
mcgs of EE alone). The two brands that are FDA-approved for treatment
of acne vulgaris are Estrostep and Ortho Tri-Cyclen, Cyclessa is a lowdose tripbasic OCP that contains less estrogen than Tri-Cyclen and other
triphasic pills; it contains 25 mcg/day of ethinyl estradiol plus
desogestrel [0.1, 0.125, and 0.15 mg/day] in each phase (49).
Yasmin is an oral contraceptive with 30 mcg of EE and the
progestin, drospirenone (43). This progestin is a synthetic version of
progesterone as well as a spironolactone analog that can lead to
potassium retention; 3 mg of drospirenone is equivalent to 25 mg of
spironolactone. This OCP is contraindictced in females with renal,
hepatic or adrenal insufficiency (43). It is unclear if this OCP has any
advantages over other OCPs and its effect on acne is similar to other
OCPs. One report notes 40 cases of VTB with 2 deaths in Europe in
women taking Yasmin (50).
Seasonale is an OCP with 30 mcg EE and 0.15 mg levonorgestrel
(51). It provides continuous combined estrogen plus progestin for 84
days followed by seven days of placebo, so that only four menses occur
per year. Lybrel is another continuous use oral contraceptive that
contains 0.09 mg of levonorgestrel and 0.02 mg of ethinyl estradiol. This
extended cycling (e.g., absence of menses for several months) is
especially helpful for adolescents who have medical problems that are
worsened by menstruation or have significant adverse symptoms due to
menstruation, such as dysmenorrhea or menorrhagia (see table 9) (52).
However, extended cycling is associated with increased breakthrough
bleeding, especially in the first year of use (51). Some females may be
interested in extended cycling for life style reasons. For example, an
athlete may wish to extend her cycle to avoid menses during athletic
competitions or vacations. Extended cycling can be accomplished with
any OCP by omitting the placebo pills and starting a new pack of OCPs
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after 21. days. The Patch and NuvaRing have not been studied
for extended or continuous use regimens.
Table 9. Conditions that may benefit from extended cycling

Dysmenorrhea
Premenstrual Tension Syndrome (PTS)
Menorrhagia
Iron Deficiency Anemia
Endometriosis
Headaches
Epilepsy
Rheumatoid Arthritis
Coagulapathies
Anticoagulation Therapy

Contraindications to OCPS
The World Health Organization (WHO) has published a list of medical
eligibility guidelines to provide clinicians with guidelines for OCP use in
those with various chronic illnesses that place users at increased risk of
complications (see table 10) (49,53-56). Females in WHO category 1
have no restrictions to use of the OCP, while females in category 2 have
some increased medical risk. though pregnancy risks typically exceed
OCP risks. Those in category 3 are typically not prescribed an OCP due
to increased risks, unless pregnancy risk is high and there is no other
method of contraception that is acceptable to the patient. If a condition
places the female in category 4, the individual should not be placed on
OCPs due to the high risks of significant OCP-induced adverse effects.
Table 10. WHO medical eligibility categories for OCPs)*(56-58)
Category one (no restrictions)
Antibiotics
Benign breast disease

Contraception
Benign ovarian tumors
Cervical ectropion
Dysmenorrhea,
Endometriosis
Epilepsy
Family history of breast cancer
Gestational trophoblastic disease (benign or malignant)
Headaches (mild)
History of ectopic pregnancy or abortion (postabortion after
first or
second trimester),
History of gestational diabetes
Increased STD risk
Iron deficiency anemia
Irregular menstrual bleeding
Obesity
Ovarian or endometrial cancer
Past pelvic surgery
Pelvic inflammatory disease
Postpartum at or over 21 days
Thyroid disorders (as hypo/hyperthyroidisrn, simple goiter)
Varicose veins
Various infections :malaria, tuberculosis, others)
Sexually transmitted diseases
Viral hepatitis carrier
Category two (caution)

Cervical cancer
Diabetes mellitus (uncomplicated)
Headaches (severe and if they start after beginning OCPs)
Hypertension at 140-159/100-109 mm Hg
Major surgery without prolonged immobilization
Migraine headaches without focal neurologic involvement,
Patients who have a hard time taking the OCP correctly:
drug or alcohol abuse
mental retardation
persistent history as poor OCP takers
severe psychiatric disorders
Sickle cell disease or sickle C disease

423
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Undiagnosed breast mass
Category three (usually OCP not given unless risks for pregnancy
are higher than the OCP)
Gallbladder disease
Lactating (6 weeks to 6 months),
Less than 21 days postpartum
Medications that interfere with OCP efficacy
Undiagnosed abnormal vaginal/uterine bleeding.
Category Four (OCP contraindicated)
Breast cancer
Cerebrovascular accident (active or history)
Complicated structural heart disease (with pulmonary hypertension,
atrial
fibrillation of history of subacute bacterial endocarditis)
Coronary (or ischemic) heart disease (active or history)
Deep vein thrombosis or pulmonary embolism (active of history)
Diabetes mellitus (complicated with retinopathy, neuropathy,
nephropathy)
Headaches (including migraine headaches) with focal
neurologic symptoms
Hypertension (severe: (160+/110+ mm Hg or with vascular
complications)
Lactation under 6 weeks postpartum
Liver disease (including liver cancer, benign hepatic
adenoma, active viral
hepatitis, severe cirrhosis)
Pregnancy, complicated
Surgery (involving the lower extremities and/or prolonged
immobilization
*(World Health Organization, 1996, 2000; Pettinato, 2003)
*Used with permission from Greydanus DE. Contraception. ID : Greydanus DE,
Patel DR. Pratt HD, Bhave S, eds. Course manual for adolescent health.
2002:309-24.
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CARDIOVASCULAR RISKS AND OCPs
Research has indicated an increased risk of cardiovascular
complications in females on OCPs (50,57-68). Obese and non-obese
females on birth control pills have an increased risk for pulmonary
emboli, thrombophlebitis, and vascular thromboses. Some studies note a
greater incidence of myocardial infarction and subarachnoid hemorrhage
as well (50). An absolute OCP contraindication is a past history of
venous thrombosis (VT) and the risk of VT is more significant for the
adolescent or young adult than arterial thrombosis. Significant obesity is
a VT risk factor and the risk is increased in obese OCP users (58-60).
Table 11 notes risk factors for thrombosis. In 2008 the US Food and
Drug Administration (FDA) added a label to the birth control patch that
patch users were at higher risk for venous thromboembolism than OCP
users, since patch users are exposed to higher estrogen levels than noted
with OCP users.
Table 11. Causes of thromboses

Factor V Leiden mutation
Prothrombin mutation G20210A
Protein S Deficiency
Protein C Deficie1tcy
Antthrombin III deficiency
Hyperhomocysteinemia from mutations in MTHFR gene
Deficiencies of Proteins: C, S, and antithrombin III
Tobacco use
Other medical risk factors: immobilization, surgery, severe illness
Others: cancer or pregnancy

Cardiovascular deaths from venous and arterial complications in
non-smoking females aged 20-24 years is 2-6 per million per year (57).
There is a 3-6 fold increased lisle factor for VT development in OCP
users and the risk for VT is higher with desogestrel versus levonorgestrel
(15,57, 61). The VT risk in the general population is 4 per 100,000
women per year, 10-30 for those on OCPs, and 60 for females who are
pregnant or postpartum (57,62-64) (see table 12). Most individuals who

,.'
'
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develop venous thrombosis do not have identified VT risk factors (see
table 11).
Table 12. Rate of non-fatal tbromboembolism in females (57,62-64)
1. No risk conditions: 4/100,000
2. Low-dose OCPS: 10-30/100,000
a. 10-15: on norgestimate or levonorgestrel OCP
b. 20-30 on desogestrel OCP
3. Pregnancy: 60/100,000
4. Factor V Leiden mutation: 140 if on the OCP (32 if not on the OCP)
Table 13 lists screening questions to use when considering OCPs for
contraception. In general, if there is no overt positive family history for
VT in those under 50 years of age, one does not need to screen for factor
V Leiden or other prothrombotic mutations because of lack of costeffectiveness. However, the Factor V Leiden mutation is the most
common genetic cause of thrombophilia, with a prevalence of 3.6% in
asymptomatic women, and 23% among Caucasian women with first
episode of spontaneous venous thromboembolism. Factor V Leiden
accounts for up to 20% of first-time VT-this prothrombin mutation
leads to a 2-4 times increased risk for VT. Thus, the OCP and the patch
should not be used if there is a history of thromboembolism. The minipill (progestin-only) can be used in this situation. Other contraceptives
that can also be used include Dcpo-Provera, Mirena IUD, and barrier
methods.
Table 13. Questions about personal/family history
of thromboembolism
1. Have you or a close family member (FM) (including uncles/aunts)
have blood clots in legs or lungs?
2. Have you/close. FM been hosp. for blood clots in legs/lungs?
3. Have you or FM taken blood thinner?
4. Under what circumstances did the clot form:
Airline travel
Pregnancy
Cancer
Obesity
Immobility
Others
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Congenital heart disease
The concern with, using OCPs in those with congenital heart disease is
that complications may arise because of increased risk for
thromboembolism (TE) and endocarditis. Increased risk for TE is due to
increased circulation of clotting factors from estrogen because of
stimulation of serum globulins from the liver. OCPs and the patch are
contraindicated in cardiac conditions with cardiac shunts, congestive
heart failure, low output cardiac disorders, and coronary heart disease
(62,65-68). The OCP and patch should be avoided in those with cyanotic
heart disease and pulmonary hypertension.
Progestin-only contraceptive methods are acceptable for most
females with congenital heart diseases including the mini-pill and DepoProvera (DMPA) if the patient is stable; these patients typically are on
anticoagulation as well. The Mirena intrauterine device (IUD) and barrier
contraception are safe as well in these situations. Patients with valvular
heart disease and congenital heart disease are at risk for endocarditis for
one month or so with and after an IUD placement. Other IUD
complications at the time of IUD placement include bradycardia,
seizures, and syncope; the IUD is contraindicated if the female is on
anticoagulation, since there is increased risk of bleeding with the IUD
placement. These contraceptive methods are reviewed later in this
discussion.

Hypertension
There is a small increase in blood pressure on the OCP with a 6-8 mm
Hg rise in the systolic pressure and a 4-6 m.m Hg is the diastolic
pressure. Blood pressure should be monitored on the OCP and a lowdose OCP is acceptable for stable hypertension with no end organ disease
(67). OCPs are contraindicated in those with severe hypertension (i.e.,
systolic blood pressure > 160 mm Hg and/or diastolic blood pressure
>100 mm Hg) (67). The risk of ischemic complications is probably
slightly increased in patients with hypertension on OCPs; the US studies
suggest no risk, while European studies note some increased risk (65-68).
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Other contraceptives that are safe for patients with hypertension are
Depo-Provera, the Mirena IUD, and barrier methods.

Hyperlipidemia
Estrogen can worsen lipid patterns (increase low density lipoproteins
[LDL] and decrease high density lipoproteins) to increase risks for
coronary artery disease (CAD) risks; estrogen can also increase
triglycerides, but not to worsen CAD risks (66). Low-dose OCPs are safe
for stable hyperlipidemia but should be avoided when the LDL is over
160 mg/dl, triglycerides are over 250 mg/dl, or when multiple CAD risk
factors are present (65,66,68). These CAD risk factors include smoking,
obesity, diabetes mellitus, hypertension, and positive family history for
premature CAD (1,2,4). Progestin-only contraception are safe with
hyperlipdemia.

Obesity
Sexually active obese teens who do not want to become pregnant also
need contraception. Research notes that overweight/obese youth use
contraception less than their normal weight peers and obese females have
reduced efficacy with OCPs as well as the patch because of higher
adipose tissue sequestration, increased enzyme metabolism in the liver,
and higher basal metabolic rates (60,69). However, OCP efficacy in
obese females is higher than that noted with the use of barrier
contraception. OCPs can be a good contraceptive option for females with
obesity, polycystic ovary syndrome, acne, and hirsutism (44). In
addition, adverse pregnancy outcomes in Ibis group must be taken under
consideration (58,59, 70-72). VT risks are increased in obese females and
progestin-only contraception (i.e., the mini-pill and Depo-Provera) can
be safely used. However, there can be increased weight gain and central
redistribution of adipose tissue following use of Depo-Provera. Also
effective in obese individuals are the intravaginal ring and the IUD. In
conclusion, the safest methods of contraception for obese female adults
may be the mini-pill and the levonorgestrel IUD (58).
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Diabetes mellitus
Research notes that OCPs are safe and effective in females with wellcontrolled diabetes mellitus (types 1 and 2) who do not have such
diabetic complications as retinopathy, nephropathy, or peripheral
vascular disease (58,60). Metabolic status in diabetes is not worsened on
OCPs or the patch and the newer progestins (i.e., desogestrel,
norgestimate, or gestodene) may effect metabolism of carbohydrates less
than older progestins (66). OCPs should not be provided if there is a
history of VT, diabetic complications, or hypertension (58.60). Other
safe methods of contraception for diabetic youth include the IUD and the
mini-pill (59). If an IUD is placed in a diabetic youth, there may be an
increase in recurrent vaginal yeast infections that are resistant to standard
anti-fungal management. Depo-Provera is safe and effective in those
with diabetes, including when diabetic complications are present (65,66).

Thyroid disease
All contraception should be safe and effective in those with hyper- or
hypothyroidism; however, if the you1h is on levothyroxine for
hypothyroidism, check T4 and TSH levels after two cycles of OCPs
(65,66).

Hyperprolactinemia
If pituitary adenoma is not the cause, OCPs are safe and also helpful to
prevent further bone loss and provide effective concraception (65).

Migraine headaches
Migraine association with menses (catamenial headaches) may be due to
reduced estrogen levels at menses (65). OCPs are not contraindicated in
tension or muscular-type headaches, though the OCP should be stopped
if the female presents with severe, worsening headaches after slatting the
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OCP. Caution is recommended in using OCPs in females with a histo1y
of migraine headaches. OCPs should be stopped or avoided in those with
migraines that worsen on OCPs or in those with migraines complicated
by neurological features (i.e., auras) (1,2).
Those with migraines and neurological symptoms (i.e., complicated
migraines) have an increase risk for cerebral ischemia and
cerebrovascular accidents (CVAs) on the OCP because of the estrogen
component (73). Studies in Europe noted a four fold increase in ischemic
strokes in females with complicated migraines on the OCP while studies
in the United States suggest a two-fold increase (66). The risk of
thrombotic stroke in migrainoid females on OCPs is 8 per 100,000 at age
20 years versus 80 at age 40 years of age (66).
In summary, OCPs should not be given to those with severe
migraines or complicated migraines, including those with hemiplegic or
ophthalmoplegic types. Stop the pill if the headaches worsen in OCPs.
Those with focal neurologic features (i.e., hemiplegic or ophthalmoplegic
types) are given a WHO category of 4 (contraindication), because of the
high risk for CVAs on OCPs. 1f headaches without focal neurologic
features start after the OCP has begun, a WHO category of 2 is given. If
complex migraines are present, avoid estrogen and consider DepoProvera, the mini-pill, or the Mirena IUD in addition to barrier
contraceptives (58,59).

Epilepsy
One million females of child-bearing age have a seizure disorder and
may have reduced efficacy if placed on certain anti-epileptic medications
(74-77). Catamenial epilepsy may occur because of hormonal changes
that occur during the menstrual cycle (77). Estrogen has proconvulsant
effects and progestin has anti-convulsaut effects (74-76). Puberty itself
does not usually worsen or improve epilepsy of childhood, though
juvenile myoclonic epilepsy may develop as puberty ensues (77).
However, if seizure activity does worsen with puberty, an adjustment in
anti-seizure medications usually corrects the situation. Ethinyl estradiol
undergoes considerable first-pass metabolism as noted in table 14 while
the metabolism of progestins in summarized in table 15.
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Table 14. Metabolism of ethinyl estradiol
1. In the Gastrointestinal tract by sulfation
2. In the liver by glucuronidation or hydroxylation
a. Enzyme CYP3A4 is 1 of 7 primary isoenzymes of the P-450
enzyme system
b. CYP3A4 catalyzes the hydroxylation
3. Metabolites under conjugation and enterohepatic recirculation
(results in reabsorption of active EE)
4. Extent of enzyme induction varies depending on genetic+
environmental factors

Table 15. Metabolism of progestin
1. Synthetic progestins are eliminated through hepatic metabolism.
2. Progestins do not undergo extensive first-pass metabolism or
enterohepatic recirculation
3. CYP3A4 isozyme is involved in progestin metabolism
4. Inducer anti-epileptic medications ↑ sex hormone-binding
globulins that ↓ P
5. Levels
However, many antiepileptic dmgs (AEDs) can induce an increase in
hepatic microsomal enzymes (cytochrome P-450 system), which can
produce increased pill metabolism and decreased pill hormone
concentrations. The result is a decrease in the pill's contraceptive ability
(increased estrogen [E] metabolism, increased progestin [P] protein
binding, decreased E & P concentration with decreased contraceptive
efficacy) (76), resulting in an estimated 3.1 pregnancies per 100 women
years of use; this pregnancy rate can be significant when considering the
potential teratogenic effects of AEOs on the developing embryo (74-76).
Hepatic enzyme inducer anti-epileptic drugs are listed in table 16.
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Table 16. Inducer anti-convulsant medicatations (1,57,63,72, 74)
Phenytoin (Dilantin)
Phenobarbital
Primidone (Mysoline)
Felbamate (mild inducer) (Felbato)
Carbamazepine (Tegretol)
Oxycarbazepine (mild inducer) (Trilepal)
Topiramate (mild inducer) (Topamax)
Tiagabine
Newer AEDs have minimal interaction with OCPs. Table 17 lists
anti-epileptic drugs (AEDs) that do not cause such interference because
they do not inhibit hepatic microsomal enzymes; they include valproic
acid (Depakote) and zonisamide (weak inhibitor [Zonegran]) and those
with no effect on P-450 enzymes and no decrease in estrogen or
progestin levels. Use of OCPs and lamotrigine may reduce lamotrigine
levels and close monitoring is recommended (74-76). There can also be
drug interference in those taking AEDs, OCPs., and other drugs that are
metabolized via the P-450 pathway, that affect drug concentrations; these
include ketoconazole, fluoxetine, erythromycin, propoxyphene, others.
AEDs have various side effects including increased sexual dysfunction,
irregular menses, and ovulatory failure. For example, valproate has
increased risks for anovulation, polycystic ovarian syndrome, polycysticappearing ovaries, and hyperinsulinemia.
Table 17. AEDs that do not effect OCP hormonal levels
(1,57,63,72, 74)
Gabapentin (Neurontin)
Ethosuximide (Z rontin)
Tiagabine
Lamotrigine(Lamietal)
Levetiracetam (Keppra)
Pregabalin
Vigabacrin (Sabril)
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Management: Epilepsy and OCPs
Some clinicians conclude that the contraceptive efficacy of inducer
AEDs with OCPs is acceptable and use these AEDs along with the OCP.
Some clinicians seek to avoid such interference by prescribing higher
estrogen OCPs (i.e, 50 mcg to 100 mcg ethinyl estradiol) when patients
are taking inducer AEDs, while other clinicians increase the frequency of
OCP closing and reduce the pill-free interval of seven days along with
adding barrier contraception (74-76). A more potent progestin may be
used if break-through bleeding occurs. As noted, anti-epileptic drugs do
have a teratogenic potential and thus, these patients should take folate to
lower the risk for neural tube defects, while also taking calcium and
vitamin D supplementation to lower risks for AED-induced bone disease
(78).
The amount of AEDs can be altered during the menstrual cycle to
reduce side effects. For example, chose with reduction of the AED during
the OCP placebo week may experience reduced drug-induced headaches
(66). The mini-pill has reduced contraceptive efficacy in those on AEDs,
due to low progestin levels and is not recommended. However, DepoProvera is effective and may have anti-convulsant effects, though it has
not been studied in this regard. The IUD (Mirena and copper) and barrier
contraception are also recommended in patients on inducer AEDs that
need contraception.

Arteriovenous malformation (A VM) with epilepsy
There is no increase in a hemorrhagic complication in those with an
AVM and epilepsy during pregnancy or labor, if the AVM has been
surgically treated. There is no research that the OCP will increase
thrombosis in a patient with an A VM on an OCP (79). An AVM in the
gastrointestinal tract may have reduced bleeding risks on OCPs (79).

Liver disorders
Estrogen and nor-progestins are metabolized in the liver and alter
hepatocellular function, leading to increase in cholesterol, reduction in
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bile acid as well as bile secretion, and changes in bile composition. OCPs
should not be provided for those with active liver disease (WHO
category 4), including cirrhosis and hepatitis (65).The OCP or patch can
be used if liver function returns to normal, though the effect of obesityrelated NASH (nonalcoholic steatohcpatitis) on OCPs is not clear at this
lime. Depo-Provera is acceptable unless there is increased risk for
bleeding, while barrier contraception and the Mirena IUD are acceptable
contraceptive methods if active liver disorders are present. The birth
control pill-associated hepatic cell adenoma has an estimated annual
incidence of 3.4 cases per 100,000 pill users. A variant of this benign
tumor is the focal nodular hyperplasia; on rare occasions this lesion can
rupture in the liver or peritoneum, causing a syndrome of right upper
quadrant mass, abdominal pain, right shoulder pain, and diverse
symptomatology associated with acute blood loss (1,2).
Renal disease
Pregnancy can worsen renal prognosis in those with end-stage renal
disease (ESRD) who are not on dialysis and those who are posttransplant. OCPs are safe and effective for females with ESRD, if the
renal condition is stable and there is no unpaired renal function,
hypertension, cardiovascular disease, or thromboembolism (65,66).
Systemic lupus erythematosus is considered below. In those with stable
renal disease, acceptable contraceptive methods include OCPs, the patch,
Depo-Provera, the Mirena IUD, and barrier contraceptives. OCPs are
useful for stable renal disease without complications and are beneficial to
control the hype1menorrbea often seen with chronic renal disease.
Estrogen should be avoided in those with chronic renal disease who have
significant hypertension or are bed-ridden; alternative contraceptives in
such situations include progestin-only methods or the Mirena IUD. The
IUD should be avoided in those with risk of infections (i.e., endometritis)
and with worsening anemia.
There is limited research at this point to guide decisions regarding
contraception for sexually active renal transplant females. The
medications that the renal transplant patient takes should be considered,
as well as the specific complications when advising on specific

Contraception

435

contraceptive methods (80). Those on estrogen contraceptive methods
should be carefully monitored, while Depo-Provera and banier methods
seem to be safe. Use of IUDs may cause complications, since these
medications
on
and
immunosuppressive
are
females
are
imo1uoocompromised because of their chronic renal disease. IUDs
should be avoided in those on peritoneal dialysis because of the risk of
peritonitis with run insertion; if the IUD is inserted, prophylactic
antibiotics should be prescribed (80,81).

Pulmonary disorders
Some adolescent females with cystic fibrosis are fertile and are at risk for
pregnancy if sexually active. Thus, contraception is appropriate to
discuss with sexually active females who have cystic fibrosis. The
concern is that the progestin in OCPs may thicken bronchial mucus as it
does cervical mucus. However. interference with contraceptive efficacy
has not been observed and progestin is not contraindicated in those with
cystic fibrosis (82). Pulmonary embolism is a rare complication of OCPs,
as noted before. The Mirena IUD and barrier contraceptives are safe for
those with cystic fibrosis (65). Also, there is no OCP contraindication for
females with asthma. Patients with tuberculosis who are placed on antituberculosis therapy, such as rifampin, will have reduced OCP
effectiveness.

Inflammatory bowel disease
Menstruation can worsen inflammatory bowel disease (IBD) symptoms
because of menstrual-induced rise in prostaglandin levels that can worsen
contractions of the uterine and gastrointestinal muscles. Pregnancy is not
very common in females with inflammato1y bowel disease (IBD), and
can worsen the IBD condition. OCPs can reduce gastrointestinal
symptoms in IBD if taken with active colitis; however, there can be
limited OCP absorption with less pill effectiveness and increased breakthrough bleeding in this situation. However, contraception should be
provided to sexually active females with IBD (83). Thus, the patch may
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be best to avoid the need for gastrointestinal absorption. Depo-Provera is
effective and can be useful to reduce the incidence of menstrua1 bleeding
and subsequent anemia. Depo-Provera may be recommended in the small
percent of cases in which there is concomitant IBD and a coagulation
disorder. Bone density issues should be taken under consideration,
especially if corticosteroid therapy is administered. Barrier contraceptive
methods are safe for those with IBO who need contraception. The
Mirena IUD should be safe though research is needed to further su1dy its use
in those with IBD.

Cancer

OCPs are absolutely contraindicated in females with breast cancer,
though they may reduce the risk for ovarian and endometrial carcinoma
(1,2,84). However, estrogen and progestin receptors are found in ovarian
cancer tissue and OCPs arc avoided with ovarian cancer.

Cancer treatment: Chemotherapy and radiotherapy
If thrombocytopenia (TCP) is present, OCPs are effective and beneficial
to stop TCP-induced bleeding. Continuous OCP use is helpful, while
cyclic OCPs should be avoided for severe or prolonged TCP. OCP
absorption is reduced if there is emesis or mucositis. OCPs should be
avoided if severe gastrointestinal side effects develop. For example, the
gastrointestinal flora may change as a result of treatment-induced
diarrheal cycles. The presence of infections or antibiotic use alter gastrohepatic circulation that can result in reduced OCP effectiveness. The
OCP should be avoided in those with a history of thrombosis, as noted
earlier.
Drug interactions may affect OCP use, as for example, with rifampin
or rifabutin that can decrease OCP levels. Also, OCPs can reduce drug
clearance, as, for example, noted with prednisolone. Careful monitoring
is needed if cyclosporine is used, while OCPs should be avoided in those
receiving allogenic bone marrow transplants taking cyclosporine and
prednisolone in order to prevent the development of graft-versus-host
disease and graft rejection.
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Other contraceptives in cancer patients
The mini-pill is the first choice of contraception if the patient is receiving
chemotherapy; ii should be avoided with a positive history of an ectopic
pregnancy and if the patient is taking certain medications such as
griscofulvin, rifampicin, or some anti-convulsant drugs. If there is active
vomiting or mucositis, OCP absorption may not occur. Depo-Provera is
not given if chemotherapy occurs due to the potential occurrence of
infection with blood cell changes (i.e., neutropenia or thrombocytopenia
[TCP]) or the occurrence of hematoma with an injection. Depo-Provera
may worsen bone loss already noted in some receiving chemotherapy.
Contraceptive implants can cause complications in those with TCP and
irregular bleeding, while these potential difficulties can be acceptable if the
patient is stable and only brief or transient TCP occurs. The IUD should be
avoided in females with neutropenia and a TCP.

HIV
Drug interactions may occur between HIV medications and OCPs. For
example, some HIV medications (as efavirenz or atazanavir) increase
ethinyl estradiol, while others (nevirapine and lopinavir/ritonavir)
decrease estrogen (59,85). Depo-Provera is effective in females with HIV
and there is minimal interaction with HIV medications, such as
nelfinavir, efavirenz, nevirapine or nucleoside analogues (85,86). The
IUD is also effective and safe in patients with HIV.

Rheumatological disorders (RD)
The use of OCPs is problematic in females with rheurnacologic disorders
(RD) because of the concern with the risk of thrombosis and
potential RD exacerbations. These risks are worsened with the amount of
ethinyl estradiol and progestin type (87). Research suggests that there is
no worsening of systemic lupus erythematosus (SLE) or increased SLE
flare ups if these females are taking OCPs and the patient has stable SLE (87).
There may be drug interactions between RD medications and OCPs.
Estrogen-containing contraceptives should be avoided in those with
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antiphospholipid antibody (aPL) syndrome because of an increased risk
for thrombosis, as noted below. Progestin-only contraception should be
used in those with aPL syndrome if a reduction in menstrual bleeding is
needed (as with Depo-Provera) and if the patient needs anticoagulation.

Antiphospholipid-antibody (aPL) syndrome
Thrombosis is increased in aPL syndrome, especially if there are
additional risk factors, as noted in table 11. The SELENA study (Safety
of Estrogen in Lupus Erythematosus National Assessment) concludes
that OCPs should be avoided in patients with aPL syndrome who have
moderate or high titers of antiphospholipid antibodies (i.e., at or over 40
GPL or MPL units); progestin-ooly contraception should be used and
Depo-Provera is an acceptable contraceptive agent (87). The Mirena IUD
is also acceptable for those with the aPL syndrome.

SLE (systemic lupus erythematosus)
There is no increase in SLE exacerbations in females with stable SLE
who ate placed on OCPs and thus, OCPs are used for contraception in
these females (66,87,88). Patients with SLE should be screened for aPL
syndrome and the estrogen avoided if there is aPL syndrome, vasculitis,
or nephritis (88). More research is needed regarding use of the OCP
patch, but increased hormone levels are noted and thus, the patch should
be avoided if the OCP is contraindicated. Drospirenone (as noted in
Yasmin) can lead to hyperkalemia and is avoided in renal insufficiency.
The mini-pill and barrier contraception are acceptable for those with
SLE, while Depo-Provera is avoided because of bone loss issues
associated with this contraceptive. An IUD may lead to increased risk for
infection in SLE patients because of decreased immunity, though more
research is needed in this regard.

.·.
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Rheumatoid arthritis (RA)
OCPs and the contraceptive patch have not been shown by most research
to increase RA exacerbations, but neither do they do improve RA (87).
Androgenic OCPs with second generation pills might be best to
maximize androgenic immunosuppression. Females with severe RA
might have problems with insertion of diaphragms or vaginal rings.
Though research is limited, it is best to avoid IUDs for females with RA
who are taking immunosuppressivc medications, because of potential
infection risk. The use of barrier contraception or the TUD may also be
physically difficult in some RA patients.
The use of OCPs has not been shown to increase exacerbations of
Raynaud's disease. However, OCPs shot d be avoided if there is risk of
ischemia, atherosclerosis, or vasc11litis. There may be d111g interactions
between OCPs and RA drugs, such as corticosteroids, warfarin,
cyclosporin, and certain anticonvulsants. OCPs. the patch, and the
vaginal ring should be avoided in RA females with prolonged
immobilization and the OCP should be stopped before surgery; the
timing is varied and ranges from two weeks to two months before
planned surgery, due to negative effects of estrogen on coagulation.
Some clinicians perioperatively add heparin in such cases, in order to
reduce the risk for venous thrombosis (VT), particularly if there are other
VT risk factors present. Others add a progestin-only contraceptive
method when estrogen is stopped. Some clinicians have used DepoProvera once before surgery if contraception is needed .

Sickle cell disorders (SCD)
Pregnancy increases risks for both the mother with SCD and fetus and
thus, contraception is important for sexually active females with SCD
who do not wish to become pregnant. Since the phenomenon of sickling in
SCD is not a process of thrombosis, there is no known increased
thrombosis risk in females with SCD in OCPs; thus, OCPs should be
safe for these females, though research is limited in this regard. In
addition to effective contraception. limited research suggests that DepoProvera may reduce sickling in SCD and may be the best method of
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contraception for females with SCD [1,65]. Barrier contraceptives
are also safe in females with SCD.

Intellectual disability (mental retardation)
OCPs, the patch, and ba1Tier contraception may be difficult to use
because of limited cognitive skills in sexually active females with
intellectual disability (16,65,66). The most popular method is DepoProvera, though the issue of osteopenia should be monitored in these
female adolescents. The intrauterine device bas been used as well
(89,90). Sterilization remains a controversial issue in adolescent females
with mental retardation.

Schizophrenia
It is difficult for females with schizophrenia to take OCPs daily or use
the patch effectively; worsened moodiness may occur on some taking
oral contraception. The IUD may become a delusional focus for some
schizophrenic females and it can be very difficult to recognize JUD.
induced infection when the patient is delusional (91}. The best
contraceptive method for sexually active females with schizophrenia may
be Depo-Provera.

Drug interactions
Clinicians should review any other medications patients on OCPs a.re
taking. in order to consider possible drug interactions (see table 18)
(74,92). For example, antacids (aluminum and magnesium types) prevent
gastrointestinal absorption of OCPs, especially the progestin component;
thus, ingestion of OCPs and antacids should be separated by at least three
hours. Broad spectrum antibiotics do not interfere with OCPs, though
previous anecdotal reports suggested the opposite (1,2). However,
interference is noted with some drugs, such as rifampin, griseofulvin,
ketoconazole, and itraconazole. Serum levels of some medications can be
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affected if the patient is on OCPs, such as tricyclic antidepressants,
cyclosporine, caffeine, theophylline, and prednisolone. Warfarin levels
may be increased or decreased, while free thyroxine levels are reduced
on OCPs due to increased levels of thyroxine binding globulin.

Table 18. Potential drugs interactions with OCPs (92)
I. Potent hepatic enzyme inducer withdecreased contraceptive
efficacy
a. Rifampin
b. G1iseofulvin
c. Ketoconazole; itraconazole
II. Hepatic enzyme inducer w/o evidence of reduced efficacy
a. Phenobarbital
b. Phenytoin
c. Carbamazepine
d. Primidone
e. Elhosuximide
III. Meds that reduce EE levels with increased breakthrough bleeding
(BTB); no decreased
efficacy
a. Tricyclic antidepressants
b. Chlordiazcpoxide; diazepam
c. Theophylline
4. Other Reported Drug Interactions with COCs*
a. Aspirin; acetaminophen
1) Increased clearance of these meds if COCs added
2) Anedotal (not proven) rec: increase med doses
b. St. John's wort
1) lnhibitor of P450 isoenzymes
2) Increased breakthrough bleeding
3) Anecdotal evidence of reduced OC efficacy
*Glasier A: Drug interactions and combination oral contraceptives. Dialogues
in Contraception (Univ. So. CA) 6(5): 1-4, 2000 (http://dialogues.usc.edu)
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Miscellaneous
As previously noted, a number of minor side effects may occur with
OCP use including nausea, headaches, mood changes, and breast
tenderness; these adverse effects can be quite troublesome to adolescent
females (1 ,2, 31). These often disappear with increasing duration of OCP
use. Although many women feel that OCPs are associated with weight
gain, there is no convincing evidence that OCPs cause an increase in
weight (1,2). Breakthrough bleeding (BTB) is a common side effect of
OCP use and one of the most frequent reasons for OCP discontinuation.
In most patients, BTB decreases with consistent continued use, and there
is no need to change OCP brands because of this side effect. However, if
BTB is severe and/or unrelenting, switching to an OCP containing
norgestrel (e.g., Lo/Ovral®), norgestimate (e.g., Ortho-Cyclen®) or
levonorgestrel (e.g., Nordette®, Triphasil®) may be helpful. One can
also recommend taking two pills a day until the bleeding stops or adding
20 mcg of ethinyl estradiol for 7-10 days. It is rare that a pill with 50 mcg
of ethinyl estradiol is needed to control such bleeding.

TRANSDERMAL

HORMONAL CONTRACEPTION

Use of transdermal mechanisms for delivery of medication became
available in the early 1980s. Medications that are now available in
transdermal formulations include clonidine, estradiol, fentanyl, nicotine,
nitroglycerin, scopolamine, and testosterone (93-95). The FDA approved
the first transdermal contraceptive patch (Ortho Evra Patch) in November
of 2001. It has similar side effects as OCPs with the addition of mild to
moderate application site reactions and increased incidence of breast
symptoms and dysmenorrhea (95-101). It is not yet clear if the patch
offers any significant increase in efficacy or safety advantages over
OCPs (95). However, this method may improve compliance in some
women.
The contraceptive patch is a matchbook size device placed on the
skin (abdomen, upper outer arm, buttocks, upper torso [not the breasts]).
It consists of a three-layer matrix with an outer polyester protective layer
(light tan in color), a middle layer that contains adhesive as well as
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contraceptive steroids, and an inner, clear polyester liner that is removed
before skin application (96,97). The patch results in a daily hormone
release of 20 mcg ethinyl estradiol and 150 mcg of norelgestromin, the
primary active metabolite of norgestimate (94,98-104). The hormones are
rapidly absorbed into the blood and a steady state is reached in two days,
similar to that noted with the oral contraceptive Ortho-Cyclen. The patch is
started on day l of menses, replaced weekly for three weeks, and week four
is patch free. Each patch should be placed at a different site.
Using the contraceptive patch does not require direct genital contact or
daily compliance that makes this contraceptive method popular with many
adolescent females (105). Some may find that using the patch is more
convenient than daily pill dosing as well as more user controlled and more
readily reversible than Depo-Provera. ln addition, for those who have
difficulty swallowing pills or gastrointestinal disturbances with OCPs, the
patch may be a good alternative. There are no hormonal peaks and
troughs as noted with OCPs, and cycle control as well as ovulation
suppression is similar to Ortho-Cyclen (98-106).
As noted, the adverse effects of the patch include potential site
reactions (l.9%), a transient increase in breast tenderness, and also an
increase in dysmenorrhea (94,103,107,108). Breast symptoms may
increase with use of the patch and severity ranges from mild to moderate.
Cardiovascular side effects may be increased due to increased hormone
levels (109,110). Obesity (i.e., weight > 90 kg) results in reduced
contraceptive efficacy, but still higher than tbat noted with barrier
contraceptives (58,59,98). Dermatitis may occur with the patch and those
with exfoliative skin diseases or history of skin allergies may not be
appropriate for the patch. Break-through bleeding and/or spotting may be
more prevalent in menstrual cycles 1 and 2, than noted with OCPs. The
incidence of nausea, emotional lability, and headaches are similar to that
noted with OCPs. The patch produces a similar lipid profile, as noted with
other OCPs containing EE and norgestimate (111).
Pregnancy rates in adult women are similar when comparing the
OCP and the patch, with pregnancy rates of 0.7 -1.24 per 100 womenyears reported with the patch versus 2.18 for OCPs (98-104). Adequate
steroid levels are maintained for two days past the manufacturer's
recommended 7-day application. The efficacy is similar with various
application sites. This rate is not affected by warm humid climates,
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vigorous exercise or exposure to saunas or water baths. Table 19 notes
reasons for contraceptive failure with patch technology.
Table 19. Causes of contraceptive failure with patch technology
1. Keeping the patch on for over 7 days
2. Detachment of the patch
3. Failure to begin a new patch after 7 days being off the patch
Of the 15 pregnancies reported during clinical trials of the patch. 5
were in women who weighed over 90 kg (198 pounds) (2,62). This
finding led to a warning from the manufacturer that the patch may not be
as effective in obese women. However, there has been little research on
the efficacy of other hormonal contraceptives in obese females, so this
finding may not be limited to the patch. Of over 70,000 patches that were
used in adult females during clinical trials, only 4.7% were replaced
because they fell off (1.8%) or were partially detached (2.9%) (62).
However, one study of adolescents ages 15 to 18 noted a complete or
partial detachment rate of 35.5% (62). If the patch is off after 24 hours,
there is a need for back-up contraception for the next 7 days.

PROGESTIN-ONLY PILLS (POPS;

MINI·PILLS)

Contraceptive mechanisms of progestin-only pills (POPs) include
thickening of the cervical mucus and endometrial involution. Ovulation
is not reliably inhibited and pregnancy rates can be 1 to 3 pregnancies
per 100,000 (1,2,4,112-114). Progestins used in POPs include 0.35 mg of
norethindrone (Micronor; Nor-Q.D) and 0.075 mg of norgestrel
(Ovrette). POPs are recommended by some clinicians when estrogen is
contraindicated (e.g., patients who have severe hypertension or coronary
heart disease). POPs are generally safe for most cardiovascular disorders
including cyanosis and atrial or ventricular arrhythmias. Common side
effects of POPs include irregular uterine bleeding and amenorrhea;
because of the irregular bleeding that POPs can induce, the mini-pill
should be avoided in those with coagulation disorders (1,2,4,31).
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POPs should not be used by females who have a history of ectopic
pregnancy and taking medications such as anticonvulsants, griseofulvin,
and rifampin. POPs are not contraindicated in females with obesity; there
is no increase in VT in obese females on progestin-only pills (58-60).
POPs should be avoided if the adolescent has a history of an ectopic
pregnancy and irregular menses, if she is clearly a candidate for methods
with increased efficacy over mini-pills and if she is unlikely to be
compliant with pills. A barrier method (e.g., condoms with diaphragm or
with vaginal contraceptives) can be added to improve the overall
contraceptive efficacy of the mini-pill.

EMERGENCY CONTRACEPTIVES (ECs)
Emergency contraceptives (Post-coital contraception) are among the
most controversial and under prescribed contraceptive methods (see table
20)(115-121). A number of mechanism are noted in pregnancy
prevention including delay of ovum maturation, interference with corpus
luteum function, thickening of cervical mucus, and others; thus, EC
methods interfere with ovulation or implantation (if the egg is
fertilized)(l19,122). Whenever adolescents seek EC, they should be
counseled regarding effective contraceptive methods. A variety of OCPs
can be taken after coital activity to prevent pregnancy, including Ovral
(two pills followed in 12 hours by two more pills) and various brands
which require four pills followed by four pills in 12 hours: Lo-Ovral,
Levien and Nordette. In 1998, the FDA approved of the Preven
Emergency Kit as an EC, based on the EC method described by Albert
Yuzpe in 1974 using two pills (with ethinyl estradiol and levonorgestrel)
followed in 12 hours by two more pills.
In 1999. the FDA approved of Plan B, a progestin-only EC method
that consists of two tables of 0.75 mg of levonorgestrel (Levonelle). The
first tablet of Plan B is taken immediately after unprotected coitus and
the second tablet is taken 12 hours later; studies have shown that Plan B
is equally effective when both pills are taken at the same time, as soon as
possible after coitus (115). Because Plan B contains no estrogen, nausea
and vomiting is uncommon and there is no need to obtain a pregnancy
test before administration. Thus, Plan B may be better tolerated than
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other ECs that contain estrogen (115). Although initially approved for
use within three days of coitus, more recent studies have shown that Plan
B may be effective in pregnancy prevention if taken up to five days after
unprotected coitus (115-120). The expected pregnancy rate of 8% from
an episode of unprotected coitus in the second or third week of the
menstrual cycle is reduced to < 1 % with Plan B use (115-120). If ECs
were more widely available, they could prevent 1.7 million unintended
pregnancies and reduce abortions by 50% (116,120).
Table 20. Emergency contraceptives
• Ovral®: 2 tablets followed by 2 tablets in 12 hours
• Lo/Ovral®, Nordette® or Levlen® : 4 labs and 4 more in 12 hours
• TriPhasil® or Tri-Levlen® (yellow tabs only): 4 tabs, and 4 more in 12
hours
• Ovrette®: 20 tabs and 20 more in 12 hours
• Preven® Emergency Contraceptive Kit
• Plan B®: Levonorgestrel: 0.75 mg followed by 0.75 mg in 12 hours

EC is very effective in preventing pregnancy, yet is not well-known
among adolescents and college students. Adolescents should be clearly
taught that emergency contraceptives can be used in va1ious situations, as
listed in table 21 (118,123). Without proper instructions, youth do not
use ECs effectively. Providing the emergency contraceptive for the
patient to take home before it is needed may improve efficacy (119).
Table 22 lists barriers to the use of ECs. An EC hot line is available in
America (011-1-888-668-2528 or 011-1-888-NOT-2-LATE); there is
also a web site: http://opr.princeton.edu/ec/.
Table 21. Indications for the use of emergency contraception
Having unplanned sex without protection
Condom slipping/breaking
Dislodgment of a diaphragm, cervical cap, IUD
Missing more than 2 oral contraceptives in a row
Being over 14 weeks from the last Depo-Provera® injection.
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Table 22. Reasons for failure to use emergency contraception
1.
2.
3.
4.
5.
6.
7.
8.
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Religious/cultural pressures from the family and others
Inability to pay for the services needed to obtain contraceptives
Fear of the absence of confidentiality
Fear of contraceptive side-effects
Failure of health care providers to educate students about ECs
Failure of health care providers 10 prescribe ECs
Fear of liability
Fear it will undermine the youth's use of more efficacious
contraception

A copper-containing IUD can be used for EC by inserting it up to
five days after unprotected sex anywhere in the cycle or up to five days
after post expected ovulation in a female with regular cycle, which
inhibits fertilization. It can remain in situ for long term contraception if
desired. Mirena IUS (Intrauterine System) should not be used for
emergency contraception (124). Contraindications to emergency
contraception include existing pregnancy, known acute porphyria, and
current warfarin treatment; in the latter situation, anticoagulation may be
altered and then coagulation monitoring is necessary (124).
Abstinence is recommended for two weeks after EC administration,
while regular contraceptive methods should be started right away, with
the exception of Depo-Provera which is best to be delayed for two weeks
until pregnancy is ruled out. Pregnancy and sexually transmitted disease
testing is recommended two weeks after E C administration. Menstruation
usually returns within seven days of the anticipated day. Providing E C
information does not lead to youth to unprotected sex habits or decrease
the use of regular contraceptive methods (123).

Vaginal ring
The NuvaRing is a soft, flexible, transparent vaginal ring made of an
ethylene vinyl acetate copolymer. It has an outer diameter of 54 mm and
a cross-section of 4 mm (124). There are two steroid reservoir cores in
the ring that provide a daily hormonal release of 15 mcg of ethinyl
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estradiol CEE) and 120 mcg of etonogestrel (an active metabolite of
desogestrel) (106,107). Etonogestrel implants with depot testosterone is
under study asa long-acting male contraceptive (125).
The NuvaRing provides hormone bio-availability comparable to an
oral contraceptive, such as Desogen or Ortho-Cept. It is inserted by the
female and removed after three weeks. After one week, a new ring is
inserted for the next month. If the ring is expelled, it is washed and
reinserted; if it is out over three hours, a back-up contraceptive method is
recommended until the ring is back in place for seven days in a row. This
contraceptive method is popular with college students who are
comfortable with their bodies and accept this form of contraceptive
technology. Patients should be educated that the ring does not prevent
STDs, but provides contraceptive efficacy similar to combined oral
contraceptive pills (126, 127). It can be used successfully by adolescent
females who are educated about their bodies and this contraceptive
method (31,128).
Advantages of the intravaginal ring are listed in table 23 (126-131).
Studies have shown that this contraceptive method is well-accepted by
adult women and their partners (132-134). Side effects include prolonged
menstrual bleeding lasting > 7 days in 25% of cycles, vaginal discomfort,
vaginitis, and foreign body sensation. The other side effects noted in
those using the NuvaRing are similar to OCP users, including an
increased risk of thrombosis. There is usually less irregular bleeding than
seen with OCPs. Obesity itself does not affect the contraceptive efficacy,
though extremely obese females may have trouble inserting the ring. As
ovulation returns during the first cycle after stopping ring use, there is the
possibility of pregnancy immediately after discontinuing use of the ring
(135).

Table 23. Advantages of the Nuva ring
Good contraceptive efficacy
Continuous hormone release
Gastrointestinal absorption not required
Easily inserted and remove by the wearer
Rapid return toovulation after stopping
Confidential method
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V AGINAL BARRIER CONTRACEPTIVES
Barrier contraceptives are listed in table 24 and are potentially good
contraceptive methods for those who are highly motivated to avoid
pregnancy, are comfortable with their bodies, and can use these methods
correctly with each act of coitus (1,2,136). Some adolescents are well
motivated and may choose these techniques over others discussed in this
article.
Table 24. Vaginal barrier contraceptives

Diaphragm
Cervical cap (Prentif)
Vaginal contraceptive sponge (Today)
Vaginal spermicides
Female condom (Reality)
Male condom

Diaphragm and vaginal spermicides
Table 25 outlines types of diaphragms that are available and table 26 lists
contraindications to diaphragm use. Health care clinicians can learn how
to fit diaphragms, providing the female with the correct size and
instructions on how to successfully use this classic barrier method
(l37J.The diaphragm is used with vaginal cream or foam, and can be
used in conjunction with the condom for increased contraceptive
efficacy, as well as increased protection from STDs. Vaginal
contraceptives or spermicides include foams, creams, jellies,
suppositories, and a film; Table 27 lists advantages of vaginal
contraceptives (138-141). Side effects of these agents include vaginal
odor and rarely allergic reactions (138). The diaphragm has been
associated with an increased risk of urinary tract infections in some
women, such as those with diabetes mellitus. Rarely, toxic shock
syndrome has occurred in women using a vaginal diaphragm and this
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method is contraindicated in women who have a past history of toxic
shock syndrome.
Table 25. Diaphragm types
Coil-spring diaphragm (suited for general use)
A metal wire is inserted in the rim; the wire is round and spiral-coiled;
folds in one plane.
Flat-spring diaphragm (Mensinga) (suited for anteverted uterus and/or
a cervix which is long and posteriorly pointed)
It is similar to the coil-spring type but is firmer.
Matrisalus diaphragm (Bowbent) (Suited for those with a cystocele or
vaginal-wall relaxation)
Contains a steel band which is strong and flat; the band is curved and
placed in the rim.
Arching-spring diaphragm (Findley) (Suited forthose with poor muscle tone
or have a
cervix which is pointed posteriorly)
This diaphragm has a double metal spring rim; an arc is formed when
the rim is compressed.
Table 26. Contraindications tothe use of the diaphragm
Allergy to rubber or spermicides
Anteversion (severe; forward tilting of uterus)
Complete uterine prolapse
Perineal tears
Retroversion (severe; backward tilting of uterus)
Short anterior vaginal wall
Vesicovaginal (or rectovaginal) fistulas
Toxic Shock Syndrome
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Table 27. Vaginal contraceptive advantages
•
•
•
•
•
•
•

Allows the pair to share contraceptive responsibility when used
with a condom
Can reduce dyspareunia if present (vaginal lubricant)
Cost is minimal
Prescription is not needed
Provide effective contraception, especially if used in conjunction
with condom or diaphragm
Side effects are few
Useful for young women with only occasional coitus

Cervical cap
The FDA approved the cervical cap (Prentif cavity-rim cervical cap) in
1988, since it has similar contraceptive efficacy as other barrier
contraceptives (1,2). This is a small, latex cap (with spermicide added
inside) that is about half the size of a diaphragm; the cap fits around the
cervix by suction. Four cervical cap sizes are available, 25% of females
cannot be fitted, and some females find it difficult to insert the cap.
Cervical cytology screening should be done before or at the time of
fitting the cervical cap, since cervical dysplasia has been noted in some
females using a cap; the screening is also to be done 3 months after the
fitting. Cervical laceration, cervical scarring, and a history of toxic shock
syndrome are contraindications to using cervical caps.

Vaginal contraceptive sponge (Today)
This is an over-the-counter. disposable, polyurethane sponge with a
concave shape; it can be inserted up to two days before coitus and left in
place 6 to 24 hours afterward (1,2). Vaginal malodor, vulvar rash,
pruritus, candidiasis, and increased risk for urinary tract infection as well
as toxic shock syndrome may develop. Contraceptive efficacy is similar
to other barrier contraceptives. It was first introduced to the United States
market in 1983, removed in 1994, and again became available in 2005.
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Female condom
The female condom is an over-the-counter, polyurethane bag or sheath
that is placed in the vagina prior to coitus [1,142, 143]. It was FDA
approved as a contraceptive agent in 1993 and in 2005 was made of
nitrile and called FC2 with introduction to the US marker in 2007. It is
not used with a male condom. The female condom offers some STD
protection and provides contraceptive efficacy similar to other barrier
contraceptives. Negative aspects of using the female condom include
discomfort from inner ring insertion and distracting noise during coitus.

Male condom
Male condoms are recommended to reduce the risk of sexually
transmitted diseases (STDs) as well as to prevent pregnancy (144-153).
They do not eliminate the risk of STDs and are less effective in
preventing the transmission of human papillomavirus (HPV) because of
the potential wide spread presence of the HPV infection; condoms can
stimulate regression of cervical intraepithelial neoplasia (CIN) and HPV
clearance (1,2,150, 151). The contraceptive effectiveness of condoms is
equivalent to other barrier contraceptives, if used correctly with each
coital act. Advantages of condoms are listed in table 28 while reasons for
not using condoms or inconsistent condom use are listed in table 29
(144-147).
The latex condom is preferred, since it is more effective at STD
prevention (especially for viral STDs) and has much lower rates of
slippage or breakage than noted with the Kraton polyurethane condom
and lamb cecum condoms; many different kinds of condoms are
available. Latex condoms are associated with increased breakage rates
when exposed to high temperatures and/or ultraviolet light; they are also
weakened by oil-based lubricants. Latex sensitivities can develop in 7%
of the general population and 17-25% of health care workers (148).
Health care professionals should present the subject of condoms in a
positive, not negative light. Comprehensive education is needed for
proper use, as well as role-play scenarios for convincing the partner to
use condoms. Adolescents often do not use the condom and need
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clinicians to discuss negotiation skills regarding male partner's
reluctance (often) to use condoms and encouragement in this regard
(1,27,149).

Table 28. Advantages of the condom as a contraceptive
•
•
•
•
•
•
•

Allows male to actively take p:art and share in the contraception of
the pair
Effective contraceptive agent
Many types available
May decrease dyspareunia
Minimal side effects
Available without prescription
Decreases risk of sexually transmitted diseases

Table 29. Reasons given for not using condoms as contraceptives

•
•
•
•
•
•
•
•
•
•
•
•
•
•

Condom may rupture
Cost
Disrupts foreplay
Failure of clinicians to recommend condoms
Failure of pharmacists to make condoms easily available
Proper technique needed each time
Reduced penile sensation during coitus
Refusal of contraceptive responsibility
Religious beliefs
Stigma of using a method which is associated with promiscuity
and STDs
Prefers other contraceptive method
Feel they are low risk for STD acquisition
Criticism of some that condoms are not 100% effective in STD
protection and thus,
should not be used
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INJECTABLE CONTRACEPTIVES
Medroxy-progesterone acetate (Depo-Provera; PMPA) is the main
injectable contraceptive available in the United States (1,2,58,154-158).
It inhibits ovulation and induces a thin endometrium as well as thick
cervical mucus. Depo-Provera is given as an intramuscular dose of 150
mg every three months and has a pregnancy failure rate of only 0.3%. It
was approved for the treatment of endometriosis in 1960 and approved to
provide contraception in many countries in 1980 (156). FDA approval
was delayed until 1992 because of concern over possible increased risk
of breast cancer and mutagenic properties even though this contraceptive
had been used for many years in other countries; none of these concerns
have ever been substantiated. Because Depo-Provera does not contain
estrogen, it can be used by women for whom estrogen is contraindicated.
A partial list of adverse effects of Depo·Provera are listed in table 30.
There is no decreased contraceptive efficacy noted in obese females
versus normal weight females, though additional weight gain can occur
in some females on this contraceptive (see table 30) (59).
Table 30. Partial list: Side-effects of Depo-Provera

•
•
•
•
•
•
•
•
•
•
•
•

Acne
Amenorrhea
Behavioral changes (depression, anxiety, irritability)
Breast tenderness
Decreased bone density
Dizziness
Fatigue
Glucose intolerance
Hair loss
Irregular menstrual bleeding
Nausea
Weight gain
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Bone loss is noted in adolescents on this agent and thus, it should be
avoided in those at risk for low bone density, such as adolescents who
have chronic renal disease, anorexia nervosa, and possibly those who are
wheel-chair bound (1,2,4,62, 154). Depo·Provera users often stop
menstruating, especially with prolonged use. Benefits of this
contraceptive method include reduced incidence of dysmenorrhea and
premenstrual tension syndrome. It may reduce seizure activity in some
women who have epilepsy. Fertility can be delayed for one year or more
after disconti11uation due to prolonged effect of contraceptive efficacy.
Individuals with psychosis and mental retardation who are at risk for
pregnancy have been prescribed this injectable contraceptive (89. 90).
In 2000, the FDA gave approval to another injectable contraceptive,
Lunelle (5 mg estradiol cypiona1e and 25 mg medroxyprogesterone
acetate [MPA/E2C]); it is given intramuscularly every month (every 2830 days) and has very high contraceptive efficacy. It is available as
Cyclo-Provera and as Cyclofem in other countries. Because this
injectable contains estrogen, amenorrhea and dysfunctional uterine
bleeding (DUB) are less common than noted with Depo-Provera. The
mean cycle length is 28 days and there is a predicable bleeding-free
interval and less breakthrough bleeding than is noted with OCPs. There
also is a rapid return to fertility after discontinuation. The company that
manufactures this product recalled it in 2002, because of concerns about
the amount of hormones in it. Another progestin-estrogen product that is
injectable and available outside the United States is Mesigyna (with 50
mg of norethindrone and 5 mg of estradiol valerate) (154,155).

INTRAUTERINE DEVICES (IUDS)
There are three IUDs which currently are used in the United States:
Progestasert IUD, the ParaGard (Copper T380A) and the Mirena IUD
(1,2,31,157,159,169). Progestasert IUD was first made available in 1976;
it is replaced annually and has an expulsion rate of 2.7%. Paragard was
introduced in 1983 and has a lower failure rate than the Progestasert
IUD; it is replaced every 8 to 10 years and has a reported expulsion rate
of 5%. Paragard may help protect adult women against endometrial
carcinoma. There are various other copper IUDs in the world market but
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only ParaGard is available in the United States. The IUD is used by 12%
of adult women using contraception in the world versus 1% in the United
States (160).
The IUD has been linked in the past with inducing increased rates of
pelvic inflammatory disease (PID), even though careful analysis notes
that the IUD-induced risk is minimal (37). However, litigious concerns
have resulted in a situation in which most clinicians in the United States
will not insert an IUD in a female unless she is at a minimal age (often
21 years of age), is in a mutually monogamous relationship, has no
history of PID or ectopic pregnancy, and has demonstrated her fertility.
The Mirena IUD (levonorgestrel-containiog IUD; LNG-IUD) is a
second generation of steroid-releasing IUDs; it has a 32 by 32 mm Nova
T-shaped polyethylene-barium sulfate frame (11/4" tall and wide, made of
plastic) with a rervoir around the vertical stem containing silicone and
52 mg of levonorgestrel (161). Two threads for removal are attached to
the end of the stem. It is packaged in a sterile state inside an insertion
device that is disposable.
This IUD releases 20 mcg of levonorgestrel per 24 hours over the
first five years of use; the levonorgestrel released decreases to 10 µg/day
after five years. Concentrations in the plasma stabilize to 150-200 pg/ml,
less than noted with oral contraceptives or Norplant. Mirena has been
available in Europe for over 10 years and has been used by over two
million women worldwide (161). The Mirena IUD was approved by the
FDA in 2001 for five years use in the United States, though it is used in
Europe for seven to 10 years before replacement is recommended. It is a
highly effective contraceptive, with a failure rate of 0.2% in the first year
and 0.7% at five years (161-164). It is inserted before day seven of the
cycle and is not effective if inserted post-coitally. A newer insertion
device allows easy insertion with minimal uterine perforation risks. It
exerts a local effect on the endometrium, as well as the cervical mucus,
and can initially lead to systemic effects (165).
Table 31 lists the contraceptive mechanism of IUDs ( 166). Ovulation
can continue and amenorrhea may develop because of endometrial
thinning. Table 32 lists the side effects of the Mirena IUD. The most
common side effect is menstrual bleeding; there is increased bleeding
and spotting during the first 3 to 6 months after insertion, but this usually
decreases thereafter. This IUD has been used to reduce heavy menstrual
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bleeding in adult females because up to 90% of menstrual blood loss
eventually may be decreased (167-170). The use of an IUD in females
with mental retardation has been identified (89,90). Table 33 lists the
benefits of the Mirena IUD (169). Contraindications to Mirena use
include active pelvic inflammatory disease, prosthetic heart valves,
history o f subacute bacterial endocarditis, and distorted uterine cavity.
Obese females have an increased incidence of dysfunctional uterine
bleeding and endometrial hyperplasia, making the Mirena IUD a good
contraceptive choice for obese females needing contraception; there is no
decreased contraceptive efficacy due to obesity (58,59).
Table 31. IUD contraceptive mechanisms

I.
2.
3.
4.
5.
6.

Prevents fertilization
Interferes with ovum development
Interferes with sperm movement and ability to penetrate ovum
Inhibits sperm survival
Helps prevent egg release
Thickens cervical mucus
Table 32. Mirena side effects (160)

Common

Initial increased menstrual bleeding
Abdominal pain

Uncommon
Acne/other skin problems
Back pain
Breast tenderness
Headache
Nausea
Mood changes
Rare
Hypersensitivity reaction
IUD becomes embedded in myometrium
Perforation ofuterus or cervix
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IUD inserted during pregnancy (increases pregnancy complications:
Miscarriage, sepsis, premature labor, premature delivery)
Development of intrauterine pregnancy after insertion; must remove
IUD

Table 33. Benefits of Mirena IUD
Effective contraception
Eventual reduction in menstrual flow (90%)
Frequent amenorrhea
Decreased dysmenorrhea
Decreased premenstrual syndrome
Very low rates of infectious complications
May decrease PIDincidence inthe long run
Decreases ectopic pregnancy (2/10,000)
Avoids use of estrogen
No significantly increased pregnancy risk if on anti-epileptic or
other Enzyme-inducing medications
11. Rapid return to fertility (80% within one year of removal)

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

IMPLANTS
Norplant is a long-acting, levonorgestrel-containing contraceptive
designed to be implanted subcutaneously in the upper arm (1,2). Each of
the six matchstick-sized capsules is 34 mm long and 2.4 mm in diameter
and contains 36 mg of levonorgestrel. Contraindications to its use include
active thrombophlebitic or thromboembolic disorder, undiagnosed or
abnormal genital bleeding, known or suspected pregnancy, acute liver
disease (including. benign or malignant liver tumors), and known or
suspected carcinoma of the breast. It was withdrawn from the United
States market in 2000.
Implanon contains one rod (vinyl ethylene acetate polymer) that
contains etonogestrel, while the Jadelle implant (Norplant II) has two
silastic rods with levonorgestrel (15,171,172). These two implants are
FDA-approved for three years. There is no decreased efficacy with
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obesity, though some have lower etonogestrel levels (59). Some weight
gain may be noted with both implants.

STERILIZATION
Sterilization (female sterilization. vasectomy [males]) is not normally
recommended for adolescents, but has been suggested for youth with
such issues as intellectual disability/mental retardation or schizophrenia.
However, it remains a controversial issue in the United States and is
generally only appropriate for some adult females (173,174).

NATURAL FAMILY PLANNING
Natural family planning (fertility awareness; physiologic methods) is the
method based on recognition of ovulation timing. Usually, there is a
combination of daily temperature recording, cervical mucus observation,
and other symptoms (175). General information about the calendar
method is good education for youth and can help them use other
contraceptives more effectively; however. adolescents are usually not
motivated enough to correctly use natural family planning and it has a
high failure rate in youth (176).

COITUS INTERRUPTUS
Coitus interruptus is a method used by many youth and is one of the
oldest contraceptive methods. However, it is not a recommended
contraceptive method for adolescents because of its high failure rate19% per annum (1,2).
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CONCLUSIONS
Contraception is an important concept for sexually active adolescent
females to understand who do not wish to become pregnant. This chapter
has reviewed important, effective, and safe contracep1ive methods that
can be used by female youth. Promotion of sexual responsibility should
be the charge of health professionals caring for adolescents and young
adults. The framework of sexual responsibility includes prevention of
unwanted pregnancy and S1Ds. The clinician should provide
contraceptive advice chat elicits important pertinent information such as
age and sex of her partner as well as last unprotected sex and menstrual
period. Education can be given regarding appropriate information about
pregnancy and STD risk as well as contraindications to contraceptive
methods (17,177,178).
Youth who have chronic illness and are sexually active should also
be provided with safe, effective contraception, as reviewed in this
chapter. Though abstinence is a highly recommended method of
concraccption, coitus interuptus and natural family methods are not,
because of their high failure rates. Care must be utilized in prescribing an
IUD in the adolescent or college student, because of the litigious overlay
of concern for pelvic inflammatory disease, as reviewed in the IUD
section of this discussion. Finally, sterilization is a method of
contraception normally not recommended for youth.
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